Atara Biotherapeutics Inc (ATRA)

In August 2025, Atara Biotherapeutics announced its second quarter 2024 financial results and a leadership update. In September 2025, the company announced changes to its Board of Directors and a $36 million registered direct offering. In October 2025, Atara completed the transfer of Tab-cel activities to Pierre Fabre Laboratories. In November 2025, the FDA accepted the BLA for Tab-cel for Priority Review, with a PDUFA target action date of January 10, 2026. In January 2026, Atara Biotherapeutics reported its third quarter 2025 financial results, showing a net loss of $4.3 million. On February 6, 2026, the stock price gained 8.20%.

There is no indication of typical demand seasonality for Atara Biotherapeutics' products and services. Demand for critical medical treatments is generally driven by disease incidence and progression rather than seasonal factors.

Atara Biotherapeutics, operating in the Health Technology sector, focuses on developing allogeneic T-cell immunotherapies. Its primary product, Tab-cel (Ebvallo), is an allogeneic T-cell immunotherapy for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease (PTLD). Tab-cel has marketing authorization in Europe and a BLA for approval in the United States has a PDUFA target action date of January 10, 2026. In November 2023, ATA188 failed a Phase 2 study, and in March 2025, the company paused the development of its allogeneic CAR-T cell programs to focus on Ebvallo.

Atara Biotherapeutics is headquartered in Thousand Oaks, California, and develops therapies in the United States and the United Kingdom. Tab-cel (Ebvallo) is approved and marketed in the European Economic Area, the UK, and Switzerland through its partner Pierre Fabre Laboratories.

Atara Biotherapeutics' brand reputation has been influenced by clinical trial outcomes and strategic decisions. The failure of the ATA188 Phase 2 study and the FDA's Complete Response Letter (CRL) for Tab-cel negatively impacted its reputation. The successful transfer of Tab-cel activities to Pierre Fabre Laboratories and the acceptance of the BLA for Priority Review by the FDA could help rebuild confidence. The company's approval for an allogeneic T-cell immunotherapy (Ebvallo in Europe) contributes positively to its scientific standing. Workforce reductions could be perceived as challenging periods.

Atara Biotherapeutics' ownership is a mix of institutional, retail, and individual investors. Approximately 23.99% is owned by institutional investors, 40.80% by insiders, and 35.21% by public companies and individual investors. Major institutional owners include EcoR1 Capital, LLC, Redmile Group, LLC, Vanguard Group Inc, Marshall Wace, Llp, BlackRock, Inc., Mackenzie Financial Corp, Geode Capital Management, Llc, and Acadian Asset Management Llc. Panacea Innovation Ltd owns approximately 38.95% of the company's shares.